Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease: A patient-centered benefit-risk assessment - 12/02/21
, Fernando J. Martinez c, Nicola A. Hanania d, Sebastian Heidenreich a, James M. Eudicone e, Ileen Gilbert eAbstract |
Background |
A variety of dual-combination maintenance inhalers are used to treat asthma and chronic obstructive pulmonary disease (COPD). Understanding patient preferences for treatment attributes may help select an optimal treatment from the patient perspective.
Methods |
Patient preferences for maintenance inhaler device and medication attributes were elicited through a discrete choice experiment and used in benefit-risk assessments to calculate predicted choice probabilities (PrCPs) for 14 dual-combination maintenance inhalers in four treatment classes: lower- and higher-dose inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) inhalers for asthma, and ICS/LABA and long-acting muscarinic antagonist (LAMA)/LABA inhalers for COPD.
Results |
For all treatment classes, reduced exacerbations and faster onset of action were the most important attributes. For all classes, patients were willing to tolerate an extra yearly exacerbation to decrease the medication's onset of action from 30 to 5 min. For patients with asthma using lower-dose ICS/LABA (n = 497), budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pressurized metered-dose inhaler (pMDI) had the highest PrCP (28.4%), and for those using a higher-dose ICS/LABA (n = 285), PrCPs were highest for mometasone furoate/formoterol fumarate dihydrate (200 μg/5 μg) pMDI (27.0%) and budesonide/formoterol fumarate dihydrate (160 μg/4.5 μg) pMDI (26.9%). For patients with COPD using an ICS/LABA (n = 574), budesonide/formoterol fumarate dihydrate (160 μg/4.5 μg) pMDI had the highest PrCP (56.6%), and for those using a LAMA/LABA inhaler (n = 217), tiotropium/olodaterol (2.5 μg/2.5 μg) soft mist inhaler had the highest PrCP (42.3%).
Conclusions |
Patient preference data for maintenance inhaler attributes can be used to identify a preference order of inhalers in different treatment classes.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Patient preference data for maintenance inhaler attributes can be used to identify a preference order of inhalers. |
• | Patients using inhalers of different treatment classes differed only in their preferences for device type and dose counter. |
• | Differences between predicted preference and actual prescriptions highlight importance of considering the patient perspective. |
Keywords : Asthma, COPD, Patient preferences, Benefit-risk assessment
Plan
Vol 176
Article 106278- janvier 2021 Retour au numéro
Article précédent
- A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study
- Maciej Kupczyk, Paweł Majak, Piotr Kuna, Beata Asankowicz-Bargiel, Eliza Barańska, Rafał Dobek, Sławomir Garbicz, Joanna Jerzyńska, Anna Latos, Wojciech Machowiak, Bernadetta Majorek-Olechowska, Anna Olech-Cudzik, Iwona Poziomkowska-Gęsicka, Mirosława Rulewicz-Warniełło, Anna Świderska, Michał Tarnowski, Przemysław Kopyto
- The triad of current asthma, rhinitis and eczema is uncommon among adults: Prevalence, sensitization profiles, and risk factors
- Teet Pullerits, Erik P. Rönmark, Linda Ekerljung, Mona Andersson Palmqvist, Monica Arvidsson, Roxana Mincheva, Helena Backman, Hannu Kankaanranta, Pinja Ilmarinen, Madeleine Rådinger, Bo Lundbäck, Bright I. Nwaru
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?